Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
Anderson, CP; Matthay, KK; Perentesis, JP; Neglia, JP; Bailey, HH; Villablanca, JG; Groshen, S; Hasenauer, B; Maris, JM; Seeger, RC; et al.
Pediatric Blood and Cancer.
2015;
62:1739-1746.
An open invitation to join the Pediatric Proton/Photon Consortium Registry to standardize data collection in pediatric radiation oncology.
Lawell, MP; Indelicato, DJ; Paulino, AC; Hartsell, W; Laack, NN; Ermoian, RP; Perentesis, JP; Vatner, R; Perkins, S; Mangona, VS; et al.
British Journal of Radiology.
2020;
93:20190673-20190673.
The signaling axis atypical protein kinase C lambda/iota-Satb2 mediates leukemic transformation of B-cell progenitors.
Nayak, RC; Hegde, S; Althoff, MJ; Wellendorf, AM; Mohmoud, F; Perentesis, J; Reina-Campos, M; Reynaud, D; Zheng, Y; Diaz-Meco, MT; et al.
Nature Communications.
2019;
10.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al.
Science Translational Medicine.
2019;
11:eaaw8828-eaaw8828.
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016).
Widemann, BC; Lu, Y; Reinke, D; Okuno, SH; Meyer, CF; Cote, GM; Chugh, R; Milhem, MM; Hirbe, AC; Kim, A; et al.
Sarcoma.
2019;
2019:1-8.
Cancer cell metabolism: Implications for x-ray and particle radiation therapy.
Sertorio, M; Perentesis, JP; Vatner, RE; Mascia, AE; Zheng, Y; Wells, SI.
International journal of particle therapy.
2019;
5:40-48.
Improved chemotherapy modeling with RAG-based immune deficient mice.
Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O’Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC.
PLoS ONE.
2019;
14:e0225532-e0225532.
miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential.
Meyer, SE; Muench, DE; Rogers, AM; Newkold, TJ; Orr, E; O'Brien, E; Perentesis, JP; Doench, JG; Lal, A; Morris, PJ; et al.
The Journal of Experimental Medicine.
2018;
215:2115-2136.
KLF5 controls glutathione metabolism to suppress p190-BCRABL+ B-cell lymphoblastic leukemia.
Zhang, C; D'Alessandro, A; Wellendorf, AM; Mohmoud, F; Serrano-Lopez, J; Perentesis, JP; Komurov, K; Alexe, G; Stegmaier, K; Whitsett, JA; et al.
Oncotarget.
2018;
9:29665-29679.
Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN.
Weber, DC; Habrand, JL; Hoppe, BS; Kayser, CH; Laack, NN; Langendijk, JA; MacDonald, SM; McGovern, SL; Pater, L; Perentesis, JP; et al.
Radiotherapy and Oncology.
2018;
128:44-55.